Low Expression of DCXR Protein Indicates a Poor Prognosis for Hepatocellular Carcinoma Patients

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Sep 24

PMID 27658779

Citations 3

Authors

Xiaofeng Hang

Zhiqin Wu

Kaijian Chu

Guanzhen Yu

Haoran Peng

Haiguang Xin

Xiaohui Miao

Junxue Wang

Wensheng Xu

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the prognostic value of dicarbonyl/L-xylulose reductase (DCXR) in human hepatocellular carcinoma (HCC). Immunohistochemistry and tissue microarrays were used to evaluate DCXR protein expression levels. Image-Pro Plus was used to calculate the integral optic density (IOD) in each tissue sample, which represented the expression level of DCXR. DCXR proteins were found to be significantly lower in HCC tumor tissues (P < 0.0001) according to immunohistochemical analysis of DCXR protein levels in 74 paired HCC tissue and peritumoral non-cancer tissues. The prognostic value of DCXR in HCC was assessed in 290 cases of the training cohort and 74 cases of the validation cohort. Shorter overall survival (OS) time and shorter time to recurrence (TTR) in both the training and validation set were found to be associated with lower expression levels of DCXR. In the training set, the expression level of DCXR in HCC was an independent prognostic factor for OS according to univariate and multivariate analyses. In conclusion, DCXR expression is an independent prognostic factor for OS and TTR of post-operative HCC patients, and low expression levels of DCXR in HCC may indicate poor outcome of HCC patients after surgical resection.

Citing Articles

DCXR promotes cell proliferation by promoting the activity of aerobic glycolysis in breast cancer.

Jin Y, Zhang M, Tong Y, Qiu L, Ye Y, Zhao B Mol Med Rep. 2022; 27(2).

PMID: 36562355 PMC: 9827345. DOI: 10.3892/mmr.2022.12918.

Androgen-dependent alternative mRNA isoform expression in prostate cancer cells.

Munkley J, Maia T, Ibarluzea N, Livermore K, Vodak D, Ehrmann I F1000Res. 2018; 7:1189.

PMID: 30271587 PMC: 6143958. DOI: 10.12688/f1000research.15604.1.

Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.

Zahid K, Han S, Zhou F, Raza U Cell Oncol (Dordr). 2018; 42(1):55-66.

PMID: 30238408 DOI: 10.1007/s13402-018-0407-3.

References

Yang X, Xu Y, Yu B, Zhou J, Li J, Qiu S . CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res. 2009; 15(17):5518-27. DOI: 10.1158/1078-0432.CCR-09-0151. View

San Miguel C, Fundora Y, Triguero J, Muffak K, Villegas T, Becerra A . Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. Transplant Proc. 2015; 47(8):2371-3. DOI: 10.1016/j.transproceed.2015.08.020. View

Waller L, Deshpande V, Pyrsopoulos N . Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 2015; 7(26):2648-63. PMC: 4651909. DOI: 10.4254/wjh.v7.i26.2648. View

Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao Y . Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011; 21(6):401-16. PMC: 3899457. DOI: 10.2188/jea.je20100190. View

Hwang H, Ha S, Bang H, Park C . ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection. Cancer Res Treat. 2015; 47(4):853-61. PMC: 4614186. DOI: 10.4143/crt.2014.177. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P . The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics. 2014; 106:99-112. DOI: 10.1016/j.jprot.2014.04.021. View

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

El-Kabbani O, Ishikura S, Darmanin C, Carbone V, Chung R, Usami N . Crystal structure of human L-xylulose reductase holoenzyme: probing the role of Asn107 with site-directed mutagenesis. Proteins. 2004; 55(3):724-32. DOI: 10.1002/prot.20047. View

10.

Cho-Vega J, Tsavachidis S, Do K, Nakagawa J, Medeiros L, McDonnell T . Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2007; 16(12):2615-22. DOI: 10.1158/1055-9965.EPI-07-0684. View

11.

Tan N, Liu Q, Liu X, Gong Z, Zeng Y, Pan G . Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis. Histopathology. 2015; 68(2):221-9. DOI: 10.1111/his.12738. View

12.

Matsunaga T, Kamiya T, Sumi D, Kumagai Y, Kalyanaraman B, Hara A . L-Xylulose reductase is involved in 9,10-phenanthrenequinone-induced apoptosis in human T lymphoma cells. Free Radic Biol Med. 2008; 44(6):1191-202. DOI: 10.1016/j.freeradbiomed.2007.12.024. View

13.

Nakagawa J, Ishikura S, Asami J, Isaji T, Usami N, Hara A . Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney. J Biol Chem. 2002; 277(20):17883-91. DOI: 10.1074/jbc.M110703200. View

14.

Jin G, Yu W, Dong H, Zhou W, Gu Y, Yu H . SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 2013; 59(3):510-7. DOI: 10.1016/j.jhep.2013.04.028. View

15.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

16.

Bellissimo F, Pinzone M, Cacopardo B, Nunnari G . Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015; 21(42):12003-21. PMC: 4641121. DOI: 10.3748/wjg.v21.i42.12003. View

17.

Shen Q, Fan J, Yang X, Tan Y, Zhao W, Xu Y . Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012; 13(8):817-26. DOI: 10.1016/S1470-2045(12)70233-4. View

18.

Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, Pichler M . A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour Biol. 2013; 34(4):2183-8. DOI: 10.1007/s13277-013-0754-7. View

19.

Seo S, Kim H, Kim W, Shin W, Kim D, Kim K . Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015; 21(13):3928-35. PMC: 4385540. DOI: 10.3748/wjg.v21.i13.3928. View

20.

Xu Y, Yi Y, Qiu S, Gao Q, Li Y, Dai C . PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J Hepatol. 2010; 53(5):872-9. DOI: 10.1016/j.jhep.2010.05.019. View